2022 Respiratory Drug Development eBook – Demand Accelerates Devices
This fourth annual Drug Development & Delivery Respiratory eBook highlights the pMDI development path, as well as the importance of a holistic approach to that development that includes the patient and all stakeholders across the product’s life cycle.
PLATFORM TECHNOLOGY – Confident Silence: Delivering on the Promise of siRNA Therapies
Giles Campion, MD, says while the liver offers plenty of fertile ground for developing siRNAs therapies to treat many diseases, many disease-related genes are not highly expressed in the liver. For this reason, the next great challenge in the field is delivering siRNA to tissues outside the liver.
SPECIAL FEATURE – Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
GLOBAL REPORT – 2021 Global Drug Delivery & Formulation Report: Part 3, Drug Delivery and Formulation Pipeline Trends
In part 3 of this 3-part series, PharmaCircle, in collaboration with Drug Development & Delivery, provides additional insights into the nature of the current pipeline in terms of development phase, delivery route, molecule type, and disease area taken from PharmaCircle’s Pipeline Dynamics module.
AUTOINJECTOR TECHNOLOGY – De-risking Biosimilar Development With a Clinically Validated & Commercially Proven Disposable Autoinjector
Victoria Meyer, MBA, explains how for many biopharmaceutical customers, BD and the BD Physioject™ Disposable Autoinjector have offered the appropriate combination of technology, documentation, and resources required for timely success.
EXECUTIVE INTERVIEW – BIOVECTRA: mRNA & the Future of Pharma
Marc Sauer, PhD, discusses his new position, growth at BIOVECTRA, and how he believes mRNA technologies can best be leveraged to improve the lives of patients.
BIORESORBABLE POLYMERIC MATRICES – Convergence of Materials Science & Drug Development to Treat Challenging ENT Diseases
Maria Palasis, PhD, and Robert Kern, MD, review how The XTreo platform represents a unique and powerful convergence of materials science, drug development, and formulation chemistry, enabling the local delivery of medication to anatomical spaces not accessible by conventional therapeutic approaches.
EXECUTIVE INTERVIEW – Catalent: Developing & Delivering Billions of Doses of Drugs Every Year
Alessandro Maselli, President and Chief Operating Officer of Catalent, talks about his company’s unique approach to drug development partnerships as he prepares to become the company’s new President and Chief Executive Officer on July 1, 2022.
CLINICAL TRIALS SOLUTIONS – Cracking Down on the Rising Costs of Drug Development: How Pinpointing the Complexity of Individual Patients Can Improve Success Rates
Dominique Demolle, PhD, and Erica Smith, PhD, say taking a more holistic, patient-centric approach by considering patients’ individual psychology, perceptions, and beliefs provides drug developers the opportunity to quantify these interpersonal differences between patients and address this source of variability in data analysis and interpretation.
SYNTHETIC ANTI-INFECTIVES – Synthetic Polymers Offer a New Class of Anti-Infectives
James Graham believes synthetic anti-infectives offer a potential solution to the obstacles encountered by naturally derived antibiotics in the constant arms race against antimicrobial resistance.
SPECIAL FEATURE – PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal”
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
GLOBAL REPORT – 2021 Global Drug Delivery & Formulation Report: Part 2, Notable Drug Delivery and Formulation Product Approvals and Technologies of 2021
In part 2 of this 3-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on notable drug delivery and formulation product approvals.
ARTIFICIAL INTELLIGENCE – Modernizing Your Clinical Development Safety Practices With Artificial Intelligence
Updesh Dosanjh, MS, says by continuing to explore the ability of these technologies to deliver better and safer treatments, pharmaceutical companies can benefit not only the advancement of the medical community, but the quality of life of patients around the world.
EXECUTIVE INTERVIEW – Adare Pharma Solutions: The Journey to Become a Full-Service Provider
Tom Sellig, CEO at Adare Pharma Solutions, discusses his expectations for Adare and how he can leverage his 30-plus years of pharma experience to put Adare in a competitive position to address complex formulation and development challenges.
FREEZE-DRYING MICROSCOPY – Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques
Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.
EXCLUSIVE WEBINARS
WEBINAR – Hot-Melt Granulation Technology for Lipid-Based Pharmaceuticals
Join our experts Dr. Mandar Kodgule, Dr. Rahul Aware, and Dr. Agnivesh Shrivastava live as they take you through compelling case studies, current trends and developments, and insights on mastering the design of hot-melt granulation process.
ON-DEMAND WEBINAR – Exploring Pectin & the Advancement of Delayed Release Technology
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
WEBINAR – Understanding Patch Composition for Effective Transdermal Delivery
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate
Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..
WEBINAR: BPOG 2020 & USP 665 – Extractables Testing of Single-Use Systems
This webinar will explore how to conduct effective extractables and leachables (E&L) testing on plastic process materials used during pharmaceutical and biopharmaceutical manufacturing…..
EXCLUSIVE WHITEPAPERS
WHITEPAPER – Antibody-Based Drug Discovery at the Speed of Light
Learn how the combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics….
WHITEPAPER – The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation
This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how…
WHITEPAPER – Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products
Handling HPAPI drug products requires skill, expertise and knowledge of safety considerations. This whitepaper examines the importance of US based drug product manufacturing and facility requirements to safely and efficiently manufacture solid oral dosage (SOD) HPAPI products….
WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific
Learn how the Proveris by Design(TM) approach is a proven tool for successfully developing nasal spray and inhalation drug products….
WHITE PAPER – Nanoparticles in Drug Delivery & Photothermal Therapies
Download this white paper to learn more about the applications of silica and metal-based nanoparticles in drug delivery and photothermal therapy…..
EXCLUSIVE ONLINE CONTENT
Saama Collaborates With Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Clinical Development Capabilities
Saama Technologies, LLC recently announced a multi-year agreement with Merck to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to….
Catalent to Acquire Metrics Contract Services for $475 Million
Catalent, Inc. recently announced it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in….
BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients With Treatments
BD (Becton, Dickinson and Company) recently announced a collaboration agreement with Labcorp, a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize….
Valneva & Pfizer Initiate Phase 3 Study of Lyme Disease Vaccine Candidate
Valneva SE and Pfizer recently announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and….
Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor
Rigel Pharmaceuticals, Inc. and Forma Therapeutics, Inc. recently announced they have entered into an exclusive, worldwide license agreement to develop, manufacture, and commercialize….
PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
PolyPid Ltd. recently announced it has entered into an exclusive licensing agreement with ADVANZ PHARMA Corp. for the commercialization of its lead drug candidate, D-PLEX100 for the prevention of….
New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….
Avalo Therapeutics Transfers Anti-IL-18 Antibody to Apollo Therapeutics
Avalo Therapeutics, Inc. and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize….
SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth
SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
MARKET NEWS & TRENDS
